Cancer immunotherpay

February 28, 2019

Combinatorial anti-cancer therapy blocking GPC2 pathway and immune receptors enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing   Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG)  inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 28/February/2019, 8.23 am

National Science day special ********* We wish everyone a very happy national science day. On this special occasion, we are happy to announce that Bio-Med/Pharma/Therapeutic/Clinical ideas posted […]
February 28, 2019

Combinatorial anti-cancer therapy targeting CDK4/6 pathway and immune receptors enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing  Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG)  inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 28/February/2019, 7.39 am

National Science day special ********* We wish everyone a very happy national science day. On this special occasion, we are happy to announce that Bio-Med/Pharma/Therapeutic/Clinical ideas posted […]
February 24, 2019

The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: A therapeutic mix encompassing Metformin, Navitoclax, dasatinib, 2-deoxy-d-glucose (2DG) (MNDDG)  inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signaling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 25/February/2019, 1.17 am

Introduction: What they say: A recent study from Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; Broad Institute of Harvard and Massachusetts Institute […]
January 31, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing   MiRNA-129 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as CADM1, BIRC5, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 31/January/2019, `10.44 pm

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based chemotherapy targeting cancer stem cells […]